Cost-effectiveness of human papillomavirus vaccination in Germany.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Damm, OliverHorn, Johannes
Mikolajczyk, Rafael T

Kretzschmar, Mirjam E E
Kaufmann, Andreas M
Deleré, Yvonne
Ultsch, Bernhard
Wichmann, Ole
Krämer, Alexander
Greiner, Wolfgang
Issue Date
2017
Metadata
Show full item recordAbstract
The aim of this study was to assess the cost-effectiveness of human papillomavirus (HPV) vaccination in addition to the current cervical cancer screening programme in Germany using a dynamic transmission model.Citation
Cost-effectiveness of human papillomavirus vaccination in Germany. 2017, 15:18 Cost Eff Resour AllocAffiliation
Hemholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.PubMed ID
28878573Type
ArticleLanguage
enISSN
1478-7547ae974a485f413a2113503eed53cd6c53
10.1186/s12962-017-0080-9
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
- Authors: Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ
- Issue date: 2013 Feb 7
- Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
- Authors: Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA
- Issue date: 2017 Nov 1
- Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
- Authors: Armstrong EP
- Issue date: 2010 Apr
- Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
- Authors: Annemans L, Rémy V, Oyee J, Largeron N
- Issue date: 2009
- Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
- Authors: Diakite I, Nguyen S, Sabale U, Pavelyev A, Saxena K, Tajik AA, Wang W, Palmer C
- Issue date: 2023 Jan-Dec